| Symbol
| HSP90AA1
| contributors: shn/npt/pgu - updated : 22-10-2018
|
| HGNC name
| heat shock protein 90kDa alpha (cytosolic), class A member 1
|
| HGNC id
| 5253
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
in gastric cancer | | tumoral
|
| translocation
|
|
| |
with BCL6 in primary diffuse large B-cell lymphomas of the central nervous system | | constitutional
|
|
|
| loss of function
|
loss of HSP90AA1 function abolishes BRCA1-dependent DSB repair  | | tumoral
|
|
| --over
|
| |
highly expressed in leukemia cells | |
Variant & Polymorphism
| 
| |
Candidate gene
| Marker
| FNIP1/FNIP2 expression can potentially serve as a predictive indicator of tumour response to HSPAA1 inhibitors | | Therapy target
| Hsp90 protein is an attractive pharmaceutical anti-cancer target | |
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | | | |
| modification of proteins is involved in many important cellular processes | | diabete | | | |
| HSP90AA1 inhibitors might be used to modulate O-GlcNAc modification and reverse its adverse effects in diabetes and its complications and cardiovascular and neurodegenerative diseases |
| |